Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Deoxycytidine
/ analogs & derivatives
Drug Combinations
Female
Humans
Male
Middle Aged
Models, Theoretical
Oxonic Acid
/ therapeutic use
Palliative Care
/ methods
Pancreatic Neoplasms
/ drug therapy
Prognosis
Proportional Hazards Models
Retrospective Studies
Survival Analysis
Tegafur
/ therapeutic use
Treatment Outcome
Young Adult
Gemcitabine
palliative chemotherapy
pancreatic cancer
prognostic model
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
15
04
2019
revised:
23
07
2019
accepted:
29
07
2019
pubmed:
7
8
2019
medline:
22
8
2020
entrez:
7
8
2019
Statut:
ppublish
Résumé
We previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S-1 (GS). This study aimed to validate the application of the GS model in APC patients receiving chemotherapy other than the GS regimen. We retrospectively analyzed 727 APC patients who received first-line palliative chemotherapy other than the GS regimen between 2010 and 2016 at four institutions in Taiwan. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in-group survival differences with monotherapy or combination therapy. The median survival times for the good, intermediate, and poor prognostic groups were 13.4, 8.4, and 4.6 months, respectively. The hazard ratios for the comparisons of intermediate and poor to good prognostic groups were 1.51 (95% confidence interval [CI]), 1.22-1.88, P < .001) and 2.84 (95% CI, 2.34-3.45, P < .001). The best tumor responses with either partial response or stable disease were 57.5%, 40.4%, and 17.2% of patients in the good, intermediate, and poor prognostic groups (P < .001), respectively. For patients in the good prognostic group, first-line chemotherapy with monotherapy and combination therapy had similar median survival times (13.8 vs 12.9 months, P = .26), while combination therapy showed a better median survival time than monotherapy in patients in the intermediate and poor prognostic groups (8.5 vs 8.0 months, P = .038 and 5.7 vs 3.7 months, P = .001, respectively). The results of our study supported the application of the GS model as a general prognostic tool for patients with pancreatic cancer receiving first-line palliative chemotherapy with gemcitabine-based regimens.
Sections du résumé
BACKGROUND
BACKGROUND
We previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S-1 (GS). This study aimed to validate the application of the GS model in APC patients receiving chemotherapy other than the GS regimen.
PATIENTS AND METHODS
METHODS
We retrospectively analyzed 727 APC patients who received first-line palliative chemotherapy other than the GS regimen between 2010 and 2016 at four institutions in Taiwan. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in-group survival differences with monotherapy or combination therapy.
RESULTS
RESULTS
The median survival times for the good, intermediate, and poor prognostic groups were 13.4, 8.4, and 4.6 months, respectively. The hazard ratios for the comparisons of intermediate and poor to good prognostic groups were 1.51 (95% confidence interval [CI]), 1.22-1.88, P < .001) and 2.84 (95% CI, 2.34-3.45, P < .001). The best tumor responses with either partial response or stable disease were 57.5%, 40.4%, and 17.2% of patients in the good, intermediate, and poor prognostic groups (P < .001), respectively. For patients in the good prognostic group, first-line chemotherapy with monotherapy and combination therapy had similar median survival times (13.8 vs 12.9 months, P = .26), while combination therapy showed a better median survival time than monotherapy in patients in the intermediate and poor prognostic groups (8.5 vs 8.0 months, P = .038 and 5.7 vs 3.7 months, P = .001, respectively).
CONCLUSION
CONCLUSIONS
The results of our study supported the application of the GS model as a general prognostic tool for patients with pancreatic cancer receiving first-line palliative chemotherapy with gemcitabine-based regimens.
Identifiants
pubmed: 31385456
doi: 10.1002/cam4.2483
pmc: PMC6745849
doi:
Substances chimiques
Drug Combinations
0
Deoxycytidine
0W860991D6
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Gemcitabine
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5554-5563Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Int J Clin Oncol. 2016 Feb;21(1):118-25
pubmed: 26123314
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
J Cancer Res Clin Oncol. 2015 Sep;141(9):1653-60
pubmed: 25792009
Hepatogastroenterology. 2015 Mar-Apr;62(138):478-84
pubmed: 25916086
Br J Cancer. 2014 Apr 15;110(8):1943-9
pubmed: 24642625
Sci Rep. 2017 Sep 14;7(1):11524
pubmed: 28912447
J Cancer. 2018 Mar 22;9(7):1301-1307
pubmed: 29675111
BMC Cancer. 2008 Mar 28;8:82
pubmed: 18373843
Jpn J Clin Oncol. 2010 May;40(5):432-41
pubmed: 20147334
J Cancer Res Clin Oncol. 2017 Jun;143(6):1053-1059
pubmed: 28210843
J Transl Med. 2019 Jan 18;17(1):30
pubmed: 30658662
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):236-244
pubmed: 28603091
BMC Cancer. 2014 Jun 27;14:471
pubmed: 24972449
Oncology. 2011;80(3-4):175-80
pubmed: 21701231
Gastroenterol Res Pract. 2018 Jun 10;2018:2373868
pubmed: 29983708
J Clin Oncol. 2013 May 1;31(13):1640-8
pubmed: 23547081
Pancreas. 2017 Sep;46(8):1011-1017
pubmed: 28787331
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
Cancer Med. 2018 Jun 1;:
pubmed: 29856121
J BUON. 2012 Jan-Mar;17(1):102-5
pubmed: 22517701
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Cancer Med. 2019 Sep;8(12):5554-5563
pubmed: 31385456
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634387